Disc Medicine (NASDAQ:IRON) Issues Earnings Results

Disc Medicine (NASDAQ:IRON) issued its earnings results on Tuesday. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15, Briefing.com reports.

Disc Medicine Price Performance

Disc Medicine stock opened at $60.67 on Friday. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60. The company’s 50-day moving average price is $51.02 and its two-hundred day moving average price is $44.75.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IRON. Wedbush reiterated an “outperform” rating and set a $83.00 target price (up previously from $75.00) on shares of Disc Medicine in a research note on Tuesday. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $66.00 to $110.00 in a research report on Monday, November 4th. Scotiabank raised their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a report on Tuesday, October 15th. Finally, HC Wainwright boosted their price objective on Disc Medicine from $70.00 to $118.00 and gave the company a “buy” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $85.80.

Insider Transactions at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 7,538 shares of company stock valued at $437,875. Company insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.